APO-PRAVASTATIN 40 MG
PRAVASTATIN SODIUM : 40 MG · DIN 02243508 · APOTEX INC
Health Canada status: MARKETED
What is APO-PRAVASTATIN?
APO-PRAVASTATIN 40 MG contains PRAVASTATIN SODIUM : 40 MG. It is listed in the Health Canada Drug Product Database under DIN 02243508, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 27-Feb-2001. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-PRAVASTATIN used for?
APO-PRAVASTATIN is indicated as an adjunct to diet for the reduction of elevated Total and Low Density Lipoprotein Cholesterol (LDL-C) levels in patients with primary hypercholesterolemia (Types IIa and IIb), when the response to diet and other non-pharmacologic measures alone has been inadequate. In hypercholesterolemic patients without clinically evident coronary heart disease, APO-PRAVASTATIN is indicated to reduce the risk of myocardial infarction, myocardial revascularization procedures, and total mortality by reducing cardiovascular deaths. In patients with total cholesterol in the normal to moderately elevated range who have clinically evident coronary heart disease, APO-PRAVASTATIN is indicated to reduce the risk of total mortality, death due to coronary heart disease, myocardial infarction, myocardial revascularization procedures, stroke and transient ischemic attack (TIA), and total hospitalization.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is APO-PRAVASTATIN called?
The same molecule, PRAVASTATIN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| APX-Pravastatin | Latin | Australia |
| Pravachol | Latin | Australia |
| Pravastatin Sandoz | Latin | Australia, Sweden |
| PRAVASTATIN-WGR | Latin | Australia |
| Colite | Latin | South Africa |
| Arrow Pravastatin | Latin | South Africa |
| Aspen Pravastatin | Latin | South Africa |
| Prava | Latin | South Africa |
| Pravastatin Teva | Latin | Sweden |
| Pranalip | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02243508 |
|---|---|
| Brand name | APO-PRAVASTATIN |
| Generic / active ingredient | PRAVASTATIN SODIUM : 40 MG |
| Manufacturer | APOTEX INC |
| Strength | 40 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C10AA03 PRAVASTATIN |
| AHFS class | 24:06.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 27-Feb-2001 |
| Original market date | 2001-02-27 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02243508 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2243508 |
| Brand name | APO-PRAVASTATIN |
| Active ingredient / INN | PRAVASTATIN SODIUM : 40 MG |
| ATC code | C10AA03 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C10 |
| AHFS class | 24:06.08 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | APOTEX INC |
How is it administered?
Recommended starting dose: 20 mg once daily at bedtime. Range: 10-80 mg/day. May be taken without regard to meals. Adjust dose for renal/hepatic impairment or concomitant cyclosporine.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
bottles of 100 and in unit dose packages of 30 tablets
Which pack is which?
| Strength on the label | 40 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | bottles of 100 and in unit dose packages of 30 tablets |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Hypersensitivity to any ingredient; active liver disease or unexplained persistent elevations of serum transaminases (>3x ULN); pregnancy and nursing women.
Warnings and precautions
Risk of myopathy/rhabdomyolysis; monitor liver function at baseline and 12 weeks; risk of increased HbA1c/fasting glucose; caution in heavy alcohol users.
What can be used instead?
Other Canadian products sharing ATC code C10AA03 PRAVASTATIN. 51 of 126 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-PRAVASTATIN | 10 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02440644 |
| ACH-PRAVASTATIN | 20 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02440652 |
| ACH-PRAVASTATIN | 40 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02440660 |
| AG-PRAVASTATIN | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02476142 |
| AG-PRAVASTATIN | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02476150 |
| AG-PRAVASTATIN | 40 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02476169 |
| APO-PRAVASTATIN | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02243506 |
| APO-PRAVASTATIN | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02243507 |
| AURO-PRAVASTATIN | 10 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02458977 |
| AURO-PRAVASTATIN | 20 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02458985 |
Who else supplies PRAVASTATIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PRAVASTATIN appears in 291 registered pack listings across 8 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does PRAVASTATIN cost around the world?
PRAVASTATIN is listed on 7 national price registers Nexara tracks, across 169 pack listings published on 7 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 4 | 86 | 03 Sep 2026 |
| Australia | ex-manufacturer | 11 | 42 | 08 Sep 2026 |
| South Africa | single exit price | 11 | 20 | 01 Sep 2026 |
| Greece | producer price (ex-factory) | 12 | 12 | 03 Sep 2026 |
| Sweden | AIP (pharmacy purchase price) | 2 | 4 | 03 Sep 2026 |
| United Kingdom | hospital | 3 | 3 | 31 Aug 2026 |
| Saudi Arabia | public | 2 | 2 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.